Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRD | O14764 | 3/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21408866 | 0.90 | GABRD (0.51) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL30267496 | 0.90 | GABRD (0.51) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL21409353 | 0.82 | NR3C1 (0.41) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| Hydrochloric Acid SCHEMBL31138071 | 0.82 | NR3C1 (0.41) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL25596253 | 0.81 | NR3C1 (0.44) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL21408934 | 0.81 | KCNH2 (0.44) | KDM4E | |
| SCHEMBL25904549 | 0.81 | NR3C1 (0.44) | KDM4E | |
| SCHEMBL24735010 | 0.81 | NR3C1 (0.47) | — | |
| SCHEMBL29841507 | 0.81 | NR3C1 (0.47) | — | |
| Hydrochloric Acid SCHEMBL29841613 | 0.80 | NR3C1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | GABRD 2413/4885GABRA1 2007/4885GABRB1 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.